Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.33 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 3/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23694098 | 0.92 | CYP2C9 (0.41) | CYP2C9KCNH2CSF1RKDRFLT1 | |
| SCHEMBL23693739 | 0.92 | CYP2C9 (0.41) | CYP2C9KCNH2CSF1RKDRFLT1 | |
| SCHEMBL23693732 | 0.91 | CYP2C9 (0.52) | CYP2C9KCNH2MAP2K2MAP2K1CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL25208836 | 0.87 | CYP2C9 (0.48) | CYP2C9KCNH2MAP2K2MAP2K1CYP2C19 | |
| SCHEMBL24927715 | 0.84 | CYP2C9 (0.34) | CYP2C9KCNH2 | |
| SCHEMBL23694575 | 0.83 | MAP2K1 (0.39) | KCNH2CSF1RMAP2K2MAP2K1CYP46A1 | |
| SCHEMBL31401831 | 0.82 | CSF1R (0.42) | KCNH2CSF1RMAP2K2MAP2K1SCN5A | |
| SCHEMBL23694149 | 0.82 | CSF1R (0.42) | KCNH2CSF1RMAP2K2MAP2K1SCN5A | |
| SCHEMBL23694099 | 0.82 | CYP2C9 (0.52) | CYP2C9KCNH2MAP2K2MAP2K1CYP2C19 | |
| SCHEMBL23693735 | 0.82 | CYP2C9 (0.52) | CYP2C9KCNH2KDRMAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
| WO-2021149776-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | 中外製薬株式会社 | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | CYP2C9 1914/4885KCNH2 1995/4885CSF1R 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.